$CLPT

ClearPoint Neuro, Inc.

ClearPoint Neuro develops and commercializes integrated systems for minimally invasive neurosurgical procedures, and provides services and products for pharmaceutical and biotechnology companies developing brain therapies. Its business has two components: medical devices for neurosurgery and partnerships in biologics and drug delivery. Its products include the ClearPoint system for surgical targeting and navigation, the ClearPoint Prism Neuro Laser Therapy System, and the IRRAflow system for intracranial fluid management in neurocritical care and operating room settings. ClearPoint Neuro also sells the SmartFlow Neuro cannula and provides preclinical studies, clinical trial support, regulatory consultation, device development, and related consulting services. It makes money through sales of devices and disposable components, as well as service fees and partnership arrangements. The company assembles products at its Carlsbad, California facility and manufactures IRRAflow control units at its San Diego, California facility.

AlphAI earnings readthird quarter 2026 · OCT 28ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 MillionVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
1
0

No SEC Form 4 filings for $CLPT in the last 30 days.

See all $CLPT insider activity →
Med

ClearPoint Neuro Earnings Call Highlights Growth and Investment

ClearPoint Neuro (CLPT) reported Q3 revenue of $12.1M, up 36% YoY. Growth was driven by navigation, capital equipment, and biologics. Margins fell to 58% due to overhead and amortization. The company raised $22M to support expansion and integration. Management expects continued growth but cautioned about cash burn and regulatory risks.

ClearPoint Neuro, Inc.: ClearPoint Neuro Reports Third Quarter 2026 Results

ClearPoint Neuro (CLPT) reported Q3 2026 revenue of $12.1M, up 36% YoY. Neurosurgery navigation and therapy revenue grew 59% to $5.4M. Biologics and drug delivery revenue increased 11% to $4.9M. The company raised $22M via equity offering and had $46.2M in cash. ClearPoint updated its 2026 revenue guidance to $48M-$50M.

CLPT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning CLPT (ClearPoint Neuro, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent CLPT coverage spans earnings, financial news and market movers.

What's driving CLPT

AlphAI scores every news story that mentions CLPT with an AI model for sentiment and relevance, and aggregates insider trades from ClearPoint Neuro, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CLPT

Score
$CLPTMedEarnings

ClearPoint Neuro Reports Third Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offerin

$CLPTHighAI 8/10

ClearPoint Neuro stock tumbles on uniQure trial setback

ClearPoint Neuro (CLPT) shares dropped 24% after partner uniQure (QURE) reported disappointing trial data for its Huntington's disease treatment, AMT-130. The therapy failed to meet primary clinical measures, raising concerns about future revenue for ClearPoint Neuro, which provides delivery hardware and software for the treatment.

$CLPTMedEarnings

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a globa

Related tickers